Form D · Biotechnology

IGM Biosciences, Inc.

Mountain View, CA · CIK 0001496323

Offering snapshot reported Jul 7, 2023 · SEC filing

Reported sold
$22.5M
Offering amount: $22.5M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 26, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 7, 2023Initial$22,500,000No comparison1SEC filing
Jul 16, 2010Initial$1,302,789No comparison7SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-486206

Source: Form D, filed Jul 7, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Felix J. Baker Director
M. Kathleen Behrens Director
Lisa L. Decker Executive
George A Gauthier Executive
Thomas A Glaze Director
Julie Hambleton Director
Bruce Keyt Executive
Andrew K Klatt Director, Executive
Michael Lee Director
Michael Loberg Director
Fred M. Schwarzer Director, Executive
William Strohl Director
Misbah Tahir Executive
Chris H. Takimoto Executive
Nelson Teng M.D, Director
Christina Teng Topsoe Director
Jakob Haldor Topsoe Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
325 E Middlefield Road
Mountain View, CA, 94043